The DJS Law Group announces that it is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (NASDAQ: IOVA) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Iovance released its financial results for the first quarter of 2025 on May 8, 2025. The Company’s quarterly product revenue declined significantly from the previous period. The Company also slashed its revenue guidance for 2025 by over 40%. Shares of Iovance fell by more than 50% in intraday trading on May 8, 2025, and have not recovered in the following days.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250515406890/en/